Medtech InsightKintsugi CEO Grace Chang is hopeful that the company’s voice biomarkers technology for detecting depression and anxiety from short clips of free speech will receive the nod of approval from US regulat
ScripA mere four days after announcing a potential link-up, troubled US group Nektar Therapeutics and UK healthcare holding company PureTech have called off merger talks which had taken seasoned observers